Schrödinger: An Interesting Investment With Immense Potential
Schrödinger faces financial losses amid investment in experimental drugs. Key 2025 trial results will reveal its future ...
Cytokinetics (NASDAQ:CYTK) Raised to “Overweight” at Morgan Stanley
Cytokinetics (NASDAQ:CYTK – Get Free Report) was upgraded by Morgan Stanley from an “equal weight” rating to an “overweight” rating in a report issued on Thursday,Benzinga reports. The brokerage ...
Mumbai Biocluster: Biologics Conference 2025 Concludes Successfully, Setting New Benchmarks in Biopharmaceutical Innovation and Collaboration
The Institute of Chemical Technology, Mumbai, in collaboration with the Mumbai Biocluster, successfully hosted the 5th Annual ...
CRISPR: From Discovery To Clinic—And Charting A Path Forward
No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...
Leerink Partnrs Predicts Gilead Sciences Q1 Earnings
Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Gilead Sciences in a report ...
Dare Bioscience risks Nasdaq delisting over market value
SAN DIEGO, CA – Daré Bioscience, Inc., a biopharmaceutical company with a current market capitalization of $26.45 million and trading at $3.04 per share, is facing potential delisting from the Nasdaq ...
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025
Received overwhelming shareholder support in favour of take-private transaction with AditxtAdvanced key pipeline programs, engaged regulatory ...
Entero Therapeutics Names Richard Paolone Interim CEO
Entero Therapeutics has named Richard Paolone as interim chief executive.
Germany’s Merck in Talks to Buy SpringWorks Therapeutics
Germany’s Merck KGaA is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical ...